This week on Social Media Voce, the AVON HMO Baby 2018 Contest have got a winner, as Roche Diagnostics launches her new stellar Viral Load test.
In its unique way, Roche – the world’s leading provider of HIV viral load testing, debut her latest HIV testing solution – Cobas Plasma Separation.
This new solution was introduced to the Nigerian Market in an event that had in attendance leading health care professionals, inflencers, entrepreneurs and partners.
What Is Cobas Plasma Separation all about?
For a positive diagnosis of HIV/AIDS be made in anybody, certain criteria must be met.
One of such criteria is knowing the HIV Viral Load in the patient.
Viral Load allows for quantification of the virus in the body. It is a reliable option than some tests that works with the principle of qualifying the presence or absence of the virus.
Clinicians depends on the regular monitoring of the viral load to ensure proper care of victims.
So imagine a card that makes the viral load testing enhanced, reliable, timely and ‘less-technical’.
The cobas® Plasma Separation Card is a stable and easy-to-use sample collection device for HIV plasma viral load, simply spot a small amount of blood on the card, transport to a lab where HIV diagnostic tests can be performed.
By providing a small amount of a patient’s blood from a fingertip, this specially designed card simplifies blood collection and sample transportation.
THE EVENT – Roche Diagnostics at ASLM 2018
Social Media Voices its approval for the Cobas Plasma Separation card.
The Roche official site describes the cards thus;
The Card fundamentally changes the way plasma samples are taken and processed and allows for reliable quantitative testing of patients with HIV living in remote areas-even areas of extreme heat and humidity-while meeting WHO requirements for determining HIV viral load prior to getting treatment.
cobas® HIV-1 is an in vitro nucleic acid amplification test for the quantitation of human immunodeficiency virus type 1 (HIV-1) in EDTA plasma or from a cobas® Plasma Separation Card (PSC) dried plasma spot of HIV-1-infected individuals.
This test is intended for use in conjunction with clinical presentation and other laboratory markers for the clinical management of HIV-1-infected patients.
This test can be used for confirmation of HIV-1 infection in antibody reactive individuals and to assess patient prognosis by measuring the baseline HIV-1 level or to monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels during the course of antiretroviral treatment.